

**SARDA PROTEINS LIMITED**

Reg. Office:

G-1-177(A) Matsya Industrial Area,

Alwar-301030 (Rajasthan)

CIN: L15142RJ1991PLC006353

Phone: 0144-2881392, +919413385217

E Mail:sardaproteins@yahoo.com

Website: www.sardaproteins.com

**Date: 11.11.2017**

To,  
The Manager,  
**The Department of Corporate Services,**  
BSE Ltd.,  
25<sup>th</sup> Floor, P.J. Towers,  
Dalal Street, Fort,  
Mumbai - 400 001

Ref: Disclosures pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 ("Listing Regulations").

Ref.: Sarda Proteins Limited, Scrip Id.: 519242

Dear Sir / Ma'am,

In accordance with Regulations 33 (1) Listing Regulations, we are submitting herewith the un-audited financial results along with Limited Review Report for the quarter/half year ended on September 30, 2017.

We request you to take the same on record and inform all those concerned.

**Thanking You,  
Yours Faithfully**

**FOR SARDA PROTEINS LTD.**



**Damodar Prasad Sarda(DIN: 00763377)  
Whole Time Director & CFO**

**SARDA PROTEINS LIMITED**


Reg Off:G-1-177 (A), Matsya Industrial Area, Alwar-301030 (Rajasthan),

Phone: 0144-2881392, E Mail: sardaproteins@yahoo.com, website: www.sardaproteins.com

CIN: L15142RJ1991PLC006353

**STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED ON 30TH SEPTEMBER, 2017****Amount in Lakhs**

Particulars	Quarter Ended			Half Year Ended		Year Ended (Audited)
	30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016	31.03.2017
I. Revenue from operations	<b>185.35</b>	204.81	144.17	<b>390.16</b>	233.69	<b>610.61</b>
II. Other Income	<b>0.44</b>	0.40	1.62	<b>0.84</b>	3.50	<b>7.41</b>
III. Total Revenue (I+II)	<b>185.79</b>	205.21	145.79	<b>391.00</b>	237.19	<b>618.02</b>
IV. Expenses:						
Cost of Material Consumed	<b>0</b>	0.00	0.00	<b>0.00</b>	0.00	<b>0.00</b>
Purchase of Stock -in- Trade	<b>194.41</b>	168.88	145.24	<b>363.29</b>	216.07	<b>542.41</b>
Changes in inventories of:	<b>0</b>					
Finished Goods	<b>0</b>	0.00	0.00	<b>0.00</b>	0.00	<b>0.00</b>
Work in Progress	<b>0</b>	0.00	0.00	<b>0.00</b>	0.00	<b>0.00</b>
Stock in Trade	(18.50)	34.36	(12.85)	<b>15.86</b>	3.90	<b>53.42</b>
Employee Benefit Expenses	<b>7.32</b>	6.13	4.58	<b>13.45</b>	9.11	<b>21.01</b>
Finance Cost	<b>0.05</b>	0.08	0.41	<b>0.13</b>	1.13	<b>1.27</b>
Depreciation and Amorisatation Expenses	<b>0.39</b>	0.39	0.33	<b>0.78</b>	0.73	<b>1.45</b>
Other expenses	<b>9.86</b>	3.75	7.96	<b>13.61</b>	13.82	<b>17.60</b>
<b>Total Expenses (IV)</b>	<b>193.53</b>	213.59	145.67	<b>407.12</b>	244.76	<b>637.16</b>
V. Profit/(Loss) before exceptional items and tax (III-IV)	<b>(7.74)</b>	(8.38)	0.12	<b>(16.12)</b>	(7.57)	<b>(19.14)</b>
VI. Exceptional Items	<b>0.00</b>	0.00	0.00	<b>0.00</b>	0.00	<b>0.00</b>
VII. Profit/(Loss) before tax (V-VI)	<b>(7.74)</b>	(8.38)	0.12	<b>(16.12)</b>	(7.57)	<b>(19.14)</b>
VIII. Tax Expense:						
(1) Current Tax	<b>(0.87)</b>	0.00	0.00	<b>(0.87)</b>	0.00	<b>0.00</b>
(2) Deferred Tax	<b>(3.50)</b>	0.00	0.00	<b>(3.50)</b>	0.00	<b>(5.93)</b>
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	<b>(3.37)</b>	(8.38)	0.12	<b>(11.75)</b>	(7.57)	<b>(13.21)</b>
X. Profit/(Loss) from discontinued operations	<b>0.00</b>	0.00	0.00	<b>0.00</b>	0.00	<b>0.00</b>
XI. Tax Expenses of discontinued operations	<b>0.00</b>	0.00	0.00	<b>0.00</b>	0.00	<b>0.00</b>
XII. Profit/(Loss) from discontinued operations (after tax) (X-XI)	<b>0.00</b>	0.00	0.00	<b>0.00</b>	0.00	<b>0.00</b>
XIII. Profit/(Loss) for the period (IX+XII)	<b>(3.37)</b>	(8.38)	0.12	<b>(11.75)</b>	(7.57)	<b>(13.21)</b>
XIV. Other Comprehensive Income						
A (i) Items will not be reclassified to Profit or Loss	<b>0.00</b>	0.00	0.00	<b>0.00</b>	0.00	<b>0.00</b>
(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	<b>0.00</b>	0.00	0.00	<b>0.00</b>	0.00	<b>0.00</b>
B (i) Items will be reclassified to Profit or Loss	<b>0.00</b>	0.00	0.00	<b>0.00</b>	0.00	<b>0.00</b>
(ii) Income Tax relating to items that will be reclassified to Profit or Loss	<b>0.00</b>	0.00	0.00	<b>0.00</b>	0.00	<b>0.00</b>
XV. Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other comprehensive income for the period)	<b>(3.37)</b>	(8.38)	0.12	<b>(11.75)</b>	(7.57)	<b>(13.21)</b>
Paid up Equity Share Capital (Face Value of the Share-Rs. 10 Per Share)	<b>172.59</b>	<b>172.59</b>	<b>172.59</b>	<b>172.59</b>	172.59	<b>172.59</b>
XVI. Earnings per Equity Share (For discontinued and continuing Operations )						
(1) Basic	<b>(0.20)</b>	(0.49)	<b>0.01</b>	<b>(0.68)</b>	(0.44)	<b>(0.77)</b>
(2) Diluted	<b>(0.20)</b>	(0.49)	0.01	<b>(0.68)</b>	(0.44)	<b>(0.77)</b>



For Sarda Proteins Limited

Director

**STATEMENT OF ASSETS AND LIABILITIES FOR THE QUARTER/ HALF YEAR ENDED SEPTEMBER 30, 2017**

Particulars	Amount in Lakhs	
	As at September 30, 2017 (Unaudited)	As at March 31, 2017 (Audited)
<b>I. EQUITY AND LIABILITIES</b>		
<b>(1) Shareholders' Funds</b>		
(a) Share Capital	250.45	250.45
(b) Reserves And surplus	(10.14)	1.61
(c) Money received against share warrants	0.00	0.00
<b>(2) Share application money pending allotment</b>	0.00	0.00
<b>(3) Non Current Liabilities</b>		
(a) Long Term Borrowings	0.00	0.00
(b) Deferred Tax Liabilities (Net)	0.00	0.00
(c) Other Long term Liabilities	0.00	0.00
(d) Long-term provisions	8.55	8.55
<b>(4) Current Liabilities</b>		
(a) Short-term Borrowings	0.00	19.59
(b) Trade Payables	22.91	0.55
(c) Other Current Liabilities	2.41	12.09
(d) Short-term Provisions	0.00	0.00
<b>TOTAL</b>	<b>274.18</b>	<b>292.84</b>
<b>II. ASSETS</b>		
<b>Non-current Assets</b>		
1. (a) Fixed Assets		
(i) Tangible Assets	6.21	4.98
(ii) Intangible Assets	0.00	0.00
(iii) Capital work in progress	0.00	0.00
(iv) Intangible Assets under development	0.00	0.00
(b) Non Current Investments	1.31	1.31
(c) Deffered Tax Assets (Net)	45.17	41.67
(d) Long Term Loans and Advances	0.01	0.01
(e) Other Non Current Assets	26.95	6.15
<b>(2) Current Assets</b>		
(a) Current Investments	0.00	0.00
(b) Inventories	88.72	104.58
(c) Trade Receivables	73.54	66.31
(d) Cash and Cash Equivalents	14.53	23.71
(e) Short Term Loans And Advances	2.60	44.12
(f) Other Current Assets	15.14	0.00
<b>TOTAL</b>	<b>274.18</b>	<b>292.84</b>


**Notes:**

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on November 11, 2017.
- The format for unaudited quarterly results as prescribed in SEBI's circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI's circular dated July 05, 2016 IND-AS and schedule III (Division II) of the companies Act, 2013 which are applicable to companies that are required to comply with IND-AS.
- Segment reporting as defined in Accounting Standard -17 is not applicable as company have only one segment "Agro Products".
- An amount of Rs. 3.71 Lakhs as loss on commodity exchange has been included in other expenses
- There has been a reversal of excess provision of Income Tax of Rs. 0.86 Lakhs after assessment of earlier year.
- Share Capital includes Rs. 77.86 Lakhs as share forfeiture amount.
- There were no investors complaint pending as on 1st Oct 2017 and nor any complaints received during the quarter.

on behalf of the Board

Place: Alwar  
Date: 11.11.2017

D.P.SARDA (DIN:00763377)  
Whole-Time-Director



**For Sarda Proteins Limited**

*Sarda*  
**Director**



*Khetawat Agarwal & Co.*  
*Chartered Accountants*

## **INDEPENDENT AUDITORS REVIEW REPORT**

To,  
The Board Of Director  
**Sarda Proteins Limited**


We have reviewed the accompanying statement of standalone unaudited financial results of **Sarda proteins Limited** for the quarter and three months ended September 30, 2017, being submitted by the Company pursuant to the requirements of Regulation 33 of Securities and Exchange Board Of India (Listing obligations and Disclosures Requirements) Regulations, 2015 as modified by circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.


This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down by the Indian Accounting Standards 34 "Interim Financial Reporting" ("IND-AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant Rules issued thereunder and other Accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Engagements to "Review of Interim Financial information reviewed by Independent Auditor of the Entity"* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone unaudited financial results read with notes thereon prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (IND-AS) specified under section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Alwar  
Date: November 11, 2017



For Khetawat Agarwal & Co.  
Chartered Accountants  
FRN: 003960C  
  
Shally Agarwal  
Partner  
(M. No: 412736)

---

Office : 103, 1<sup>st</sup> Floor, City Centre Ashok Circle, Alwar-301001 (Rajasthan)  
Phone : Office 0144 - 2340924, 8104909639  
Mobile : 9414215353 (ML Agarwal)  
E-mail : khetawatagarwal21@gmail.com